bioAffinity Technologies
bioAffinity Technologies' revenue fell 34.2% to $6 million in fiscal 2025. Its operating margin was −171.6%, down from −95.6% a year earlier. Free cash flow was −$9 million. The diluted share count rose 325.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
bioAffinity Technologies lost money in fiscal 2025: a net loss of $15 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 1 | 11 | 3 | 1 | 6 |
| Debt incl. finance leases | — | — | — | 1 | 1 |
| Net debt (negative means net cash) | — | — | — | −0 | −6 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | 0.4x | 0.1x |
| Interest coverage | −2.2x | −1.6x | −214.8x | −96.8x | −238.3x |
| Current ratio | 0.1x | 10.5x | 1.8x | 0.9x | 2.6x |
| Quick ratio | 0.1x | 10.5x | 1.8x | 0.9x | 2.6x |
Cash flow
Projections
Project bioAffinity Technologies' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $1.0 million of bioAffinity Technologies shares on the open market, and 1 insider sold $1.2 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Hrt Financial Lp10% owner | Sold | 41,529 | $6.45 | $267,721 | Form 4 |
| Oct 1, 2026 | Hrt Financial Lp10% owner | Bought | 17,873 | $6.54 | $116,954 | Form 4 |
| Sep 30, 2026 | Hrt Financial Lp10% owner | Sold | 20,432 | $6.76 | $138,198 | Form 4 |
| Sep 30, 2026 | Hrt Financial Lp10% owner | Bought | 12,125 | $6.78 | $82,177 | Form 4 |
| Sep 29, 2026 | Hrt Financial Lp10% owner | Bought | 22,734 | $7.02 | $159,604 | Form 4 |
| Sep 29, 2026 | Hrt Financial Lp10% owner | Sold | 20,828 | $6.85 | $142,667 | Form 4 |
| Sep 28, 2026 | Hrt Financial Lp10% owner | Sold | 14,008 | $7.57 | $106,088 | Form 4 |
| Sep 28, 2026 | Hrt Financial Lp10% owner | Bought | 10,736 | $7.64 | $82,065 | Form 4 |
| Sep 25, 2026 | Hrt Financial Lp10% owner | Sold | 9,111 | $7.86 | $71,602 | Form 4 |
| Sep 25, 2026 | Hrt Financial Lp10% owner | Bought | 7,271 | $7.81 | $56,761 | Form 4 |
| Sep 24, 2026 | Hrt Financial Lp10% owner | Bought | 30,065 | $7.67 | $230,538 | Form 4 |
| Sep 24, 2026 | Hrt Financial Lp10% owner | Sold | 27,246 | $7.75 | $211,293 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | 3 of 8 |
| Rule of 40 | −62.2% | −59.9% | −186.6% |
| Altman Z'' | −21.31 | −35.80 | −22.01 |
| Accruals ratio | −18.6% | −24.1% | −63.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | Pass |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | — | — | 3 of 8 |
Compare
Put bioAffinity Technologies side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| bioAffinity Technologies | FY25 | −34.2% | −171.6% | −152.4% | −400.1% | — | 3 | |
| Quantum-Si | FY25 | −20.3% | −4,766.0% | −3,991.5% | — | — | 1 | Compare |
| Seer | FY25 | 17.0% | −470.4% | −278.9% | — | — | — | Compare |
| OmniAb | FY25 | −29.3% | −369.5% | −198.3% | — | — | — | Compare |
| Precipio | FY25 | 29.8% | −5.0% | 1.5% | −7.8% | −37.4x | 7 | Compare |
5 years of figures
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | 7 | 8 | 9 | 6 |
| Revenue growth | — | — | 14.5% | 18.5% | −34.2% |
| Gross profit | — | 0 | — | — | — |
| Research and development | 1 | 1 | 2 | 2 | 1 |
| Operating income | −2 | −4 | −8 | −9 | −11 |
| Net income | −6 | −8 | −8 | −9 | −15 |
| Diluted EPS (US$) | — | −54.30 | −27.30 | −22.50 | −8.66 |
| Diluted shares (millions) | 0 | 0 | 0 | 0 | 2 |
| Cash flow | |||||
| Cash from operations | −2 | −4 | −6 | −7 | −9 |
| Capital expenditure | — | 0 | 0 | 0 | 0 |
| Free cash flow | — | −4 | −6 | −7 | −9 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 2 | 0 | 0 |
| Stock-based compensation | 0 | 0 | 1 | 1 | 1 |
| Balance sheet at fiscal year end | |||||
| Cash and short-term investments | 1 | 11 | 3 | 1 | 6 |
| Debt incl. finance leases | — | — | — | 1 | 1 |
| Total assets | 2 | 12 | 8 | 6 | 11 |
| Total liabilities | 13 | 1 | 3 | 4 | 4 |
| Shareholders' equity | −16 | 11 | 5 | 3 | 7 |
| Margins and ratios | |||||
| Gross margin | — | 0.1% | — | — | — |
| Operating margin | — | −58.1% | −100.9% | −95.6% | −171.6% |
| Net margin | — | −118.2% | −100.5% | −96.6% | −242.0% |
| Free cash flow margin | — | −62.2% | −76.7% | −78.4% | −152.4% |
| Rule of 40 (growth + FCF margin) | — | — | −62.2% | −59.9% | −186.6% |
| Return on capital | — | — | — | — | −400.1% |
| Return on equity | — | — | −99.8% | −242.4% | −301.8% |
| Return on assets | — | −119.6% | −77.8% | −122.7% | −170.7% |
| Net debt to EBITDA | — | — | — | — | — |